Svenska
MENUMENU

Exceptional performance of IMMray™ PanCan-d in retrospective studies

IMMray™ PanCan-d detects 98% of pancreatic cancers in the largest retrospective studies covering in total 1,800 blood samples

IMMray™ PanCan-d utilizes the company’s proprietary IMMray™ technology platform based on antibody microarray analysis. A serum protein signature that can discriminate between pancreatic cancer patients with stage I, II, III, and IV has been derived from clinical studies covering about 2500 patient samples. Work has been carried out in three phases: the discovery phase, the pre-validation phase and the validation phase.

Four large discovery studies conducted in collaboration with CREATE Health Translational Cancer Center generated IMMray™ PanCan-d biomarker signature. The diagnostic test was pre-validated in a Scandinavian cohort covering about 1400 samples of all stages of pancreatic cancer (I-IV).  Immunovia’s test could differentiate with 96% accuracy patients with early resectable stages of pancreatic cancer, stage I and II, from the healthy controls. When analyzing all stages of pancreatic cancer, the accuracy of Immunovia´s test was reported as high as 98%.

To validate the performance of IMMray™ PanCan-d for early detection of pancreatic cancer, a second retrospective study was performed in a U.S. cohort of 362 blood samples from the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) in Portland USA. When analyzing all stages of pancreatic cancer, the accuracy of Immunovia´s test remains as high as 96%.

These extremely encouraging results of 96% accuracy for IMMray™ PanCan-d, from two completely different patient cohorts collected independently on different continents in retrospective studies covering in total 238 blood samples from stages I and II, 586 blood samples from stages I to IV and 1107 healthy controls justified Immunovias  strategy to perform large, multicenter prospective studies for early detection of pancreatic cancer in high risk groups.

 

References:

  1. Ingvarsson J et al.Proteomics 2008 8(11):2211-9.
  2. Wingren et al. Cancer Res. 2012 15;72(10):2481-90.
  3. Gerdtsson et al. Int Journal of Proteomics 2015;2015:587250.
  4. Gerdtsson et al. J Mol Oncol, 2016. 10, 1305-1316.
  5. Mellby et al. A serum biomarker signature based-liquid biopsy for diagnosis of early stage pancreatic cancer. Manuscript submitted March 2018.

 

 

 

 

 

Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form.

Press releases
Financial reports